Severing ties: Illumina sells shares in Oxford Nanopore
This article was originally published in Clinica
Executive Summary
Illumina has gained £56.4m ($90.6m) from the sale of its minority shareholding in former gene sequencing partner, now turned rival, Oxford Nanopore Technologies (ONT).